TNFRSF17 and non-Hodgkin lymphoma: Since 2017, the FDA has approved six CAR T-cell therapies for the treatment of CD19 or B-cell maturation antigen (BCMA, also referred as TNFRSF17, CD269) expressing hematological malignancies including ALL, non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).